Categories: Tech

Mandatory notice of shareholding 19 June 2025 – II

 | Source: IDEX BIOMETRICS ASA

IDEX Biometrics ASA (“IDEX”) discloses the following on behalf of a shareholder.

Reference is made to the stock exchange notice from IDEX Biometrics ASA on 15 June 2025 regarding the share issue to personnel, and the notice regarding mandatory notification of trades on 20 June 2025. The subscription and allocation have been completed on 19 June 2025.

Anders Storbråten, including associated company Pinchcliffe AS, will hold 975,635,000 shares in IDEX. Following registration of the share capital increase for the personnel placement, the ownership will represent 20.62 % of the shares and voting rights in IDEX.

About this notice:

This notice was issued by Kristian Flaten, CFO, on 20 June 2025 at 04:22 CET on behalf of IDEX Biometrics ASA. The information shall be disclosed according to section 4-2 of the Norwegian Securities Trading Act (STA) and published in accordance with section 5-12 of the STA.

GlobeNews Wire

Recent Posts

Novartis Vanrafia Phase III data support slowing of kidney function decline in patients with IgA nephropathy

Basel, February 13, 2026 – Novartis today announced final results from the Phase III ALIGN…

4 days ago

January Commercial Chapter 11 Filings Increase 76% Over 2025

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- There were 956 commercial Chapter 11 filings…

1 week ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

Basel, February 6, 2026 – Novartis today broke ground on a new, state-of-the-art global Biomedical…

2 weeks ago

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjgrens disease

Basel, January 16, 2026 – Novartis today announced that the US Food and Drug Administration (FDA)…

1 month ago

Personar Appoints Former Genius Sports COO Eric Stevens as Chief Operating Officer to Scale Award-Winning Sports Technology Platform

Tuesday 13 January, 2026 LONDON – Tuesday, January 13, 2026 – Personar, the AI sports…

1 month ago

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

Basel, January 9, 2026 – Novartis, a leading global innovative medicines company, today announced plans…

1 month ago